US EditionPublished • loading... • Updated
Health Canada approves 2nd generic version of Ozempic — and it’s Canadian
The approval could lower costs for more than 1 million Canadians using semaglutide as generic competition expands, officials said.
- On Friday, Health Canada approved Toronto-based Apotex to sell a generic version of Ozempic, marking the second such authorization this week.
- Earlier this week, India's Dr. Reddy Laboratories Ltd. received the first approval, ending a four-month delay since generic versions of Ozempic became legal in Canada.
- The pan-Canadian Pharmaceutical Alliance sets initial generic prices at 75 to 85 per cent of brand-name cost, dropping to 50 per cent once a second product enters the market.
- Generic semaglutide products are expected to hit pharmacy shelves in the coming weeks, offering relief to Canadians paying up to $228 monthly for brand-name Ozempic.
- Although Apotex received tentative approval from the U.S. Food and Drug Administration, the company cannot sell the product there until the main Ozempic patent expires in 2032.
Insights by Ground AI
Podcasts & Opinions
53 Articles
53 Articles
Health Canada Approves Second Generic Version of Ozempic, First by Canadian Manufacturer
Health Canada has approved a second generic version of the diabetes drug Ozempic, marking the first such product produced by a Canadian pharmaceutical company. The semaglutide injection submitted by Canadian drugmaker Apotex was authorized after a review found it met federal safety, efficacy, and quality standards, according to a Health Canada news release. The generic drug will be administered as a once-weekly injection, consistent with existin…
·New York, United States
Read Full Article
The price difference between generic and Ozempic will depend on the number of generics approved and marketed.
·Montreal, Canada
Read Full Article
The Toronto StarReposted by 
CTV News
CTV NewsHealth Canada approves 2nd generic version of Ozempic — and it’s Canadian
TORONTO
·Toronto, Canada
Read Full ArticleCoverage Details
Total News Sources53
Leaning Left21Leaning Right3Center19Last UpdatedBias Distribution49% Left
Bias Distribution
- 49% of the sources lean Left
49% Left
L 49%
C 44%
Factuality
To view factuality data please Upgrade to Premium
